Ketamine

This article was originally published on Microdose and appears here with permission. PharmaTher is one of the psychedelic medicine industry’s best kept secrets. With several Phase 2 trials in the works, a growing pipeline of both drug development and delivery methods, and a solid working...

PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced on Wednesday that the U.S. Food and Drug Administration (FDA) has accepted an application to proceed with a Phase 2...

This article by Emily Jarvie was originally published on Psychedelic Spotlight, and appears here with permission. The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS. Psychedelic biotechnology company ...

Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin America's first network of...

This article was originally published on Microdose Psychedelic Insights and appears here with permission. While not on most people’s sexiest shroom stock list, Seelos Therapeutics has been a solid presence in the space for some time. For those who might not know, Seelos is a...

In an effort to recognize that not all drug use or possession ought to be punishable by harsh prison sentences, the United Arab Emirates (UAE) is creating amendments to longstanding laws that will stress treatment over jail time for first-time convicts of personal use and possession. Situated...

Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), recently announced it was awarded a grant for the first psychedelic treatment clinic at New York City’s Lenox Hill Hospital with which it will provide care to marginalized and underserved communities on Manhattan...

In the quest to design effective and affordable psychedelic treatments for a range of maladies that include PTSD and depression, one key thought on the minds of company executives and clinicians alike seems to be how to motivate healthcare insurance companies to cover the cost of psychedelic...

The Australian state of Victoria faces a seminal lawsuit that seeks to make MDMA available for severe mental illness. Attempting to secure permission to treat a gravely ill patient using MDMA (universally known as the street drug ecstasy), psychiatrist Dr. Eli Kotler initiated legal...

This article was originally published on Psychedelic Spotlight and appears here with permission. “As parents maintain decision-making capacity of their child’s medical care, parental consent is a key factor in the adoption of new treatments for adolescents," study authors...

Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug application to proceed with the company’s sponsored feasibility study...

Pasithea Therapeutics Corp's (NASDAQ: KTTA) wholly-owned subsidiary, Pasithea Clinics, has administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression. Pasithea Clinics commenced IV ketamine infusion therapy in Knightsbridge, London. In sub-...

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a company in the psychedelics space, will launch its first U.K.-based ketamine infusion clinic. The company went public with a $24 million IPO in the Nasdaq last month and is focused on research and discovery of new and effective treatments for...

Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) released results of a clinical study suggesting that ketamine could be as effective on its own in the treatment of depression as it is in combination with traditional antidepressants. Braxia is a medical research company with clinics providing...

Part A results from the trial of Seelos Therapeutics Inc’s (NASDAQ: SEEL) intranasal ketamine product candidate, SLS-002, and the clarity around the timing of the Part B data release call for a change in recommendation, according to Roth Capital. The Seelos Therapeutics Analyst: Jonathan...